

FRANK J. SEILER RESEARCH LABORATORY

FJSRL TECHNICAL REPORT 80-006

DECEMBER 1980

UTIC. FEB 1 7 1981

THE EFFECT OF HYPERBARIC OXYGEN ON THE GROWTH OF RHIZOPUS NIGRICANS

BY

WILLIAM J. CAIRNEY

KAREN A. O'HAIR APPROVED FOR PUBLIC RELEASE; DISTRIBUTION UNLIMITED.

PROJECT 2303

AIR FORCE SYSTEMS COMMAND

UNITED STATES AIR FORCE

· • •

81 2 17 048

FJSRL-TR-80-006

This document was prepared by the Faculty Research Division, Directorate of Chemical Sciences, Frank J. Seiler Research Laboratory, United States Air Force Academy, Colorado. The research was conducted under Project Work Unit Number 2303-F1-33, "The Effect of Hyperbaric Oxygen on the Growth of Rhizopus." Major William J. Cairney was the Project Scientist in charge of the work.

When US Government drawings, specifications or other data are used for any purpose other than a definitely related Government procurement operation, the Government thereby incurs no responsibility nor any obligation whatsoever, and the fact that the Government may have formulated, furnished or in any way supplied the said drawings, specifications or other data is not to be regarded by implication or otherwise, as in any manner licensing the holder or any other person or corporation or conveying any rights or permission to manufacture, use or sell any patented invention that may in any way be related thereto.

Inquiries concerning the technical content of this document should be addressed to the Frank J. Seiler Research Laboratory (AFSC), FJSRL/NC, USAF Academy, Colorado 80840. Phone AC 303-472-2655.

This report has been reviewed by the Chief Scientist and is releasable to the National Technical Information Service (NTIS). At NTIS it will be available to the general public, including foreign nations.

This technical report has been reviewed and is approved for publication.

WILLIAM & CAIRNEY, Major, USAF, BSC Project Scientist Director of Research/DFB

KENNETH E. SIEGENTHALER, Lt Col, USAF Director Directorate of Chemical Sciences

WILLIAM D. SIURU, Jr., Lt Col, USAF Commander

Copies of this report should not be returned unless return is required by security considerations, contractual obligations, or notice on a specific document.

Printed in the United States of America. Qualified requestors may obtain additional copies from the Defense Documentation Center. All others should apply to: National Technical Information Service

5285 Port Royal Road Springfield, Virginia 22161

	REPORT DOCUMEN	READ INSTRUCTIONS	
٠ŀ	1. REPORT NUMBER	2. GOVT ACCESSION N	BEFORE COMPLETING FORM 10 3. RECIPIENT'S CATALOG NUMBER
АI.	FJSRL-TR-80-006	ADA 095 0	127
F	4. TITLE (and Subtitle)	<u> </u>	S TYPE OF REPORT & PERIOD COVERE
	The Effect of Hyperbaric Ox	ygen on the Growth of	Summary Basant
	Rhizopus nigricans.	\sim	Summary Report.
			6. PERFORMING ORG. REPORT NUMBER
<u>,</u>	7. AUTHOR(s)		8. CONTRACT OR GRANT NUMBER(s)
	William J. Cairney, Major,		
	Karen A./O'Hair, Lt, USAF,	MSC, BS	
t	9 PERFORMING ORGANIZATION NAME AND	ADDRESS	10. PROGRAM ELEMENT, PROJECT, TASK AREA & WORK UNIT NUMBERS
Ì	Jepartment of Biology		$\frac{11}{11} = 1$
	USAFA/DFB	1	2303-F1-33
t	USAF Academy, Colorado 8084	RESS	12. REPORT DATE
	Frank J. Seiler Research La FJSRL/NC	boratory (AFSC)	December 1080
ł	- USAF Academy, Colorado 8084	.0	13. NUMBER OF PAGES
ł	14 MONITORING AGENCY NAME & ADDRES		
	1 01		UNCLASSIFIED
	1. 1. 1.		154. DECLASSIFICATION DOWNGRADING
	la secolaria		154. DECLASSIFICATION DOWNGRADING SCHEDULE N/A
Γ	6. DISTRIBUTION STATEMENT (of this Repo	ort)	
	7 DISTRIBUTION STATEMENT of the abstr	ast enterest in Block 20, if different f	from Report)
	7 DISTRIBUTION STATEMENT of the abstr	ast enterest in Block 20, it different f	rom Report)
		act enterest in Block 20, it different f	from Report)
	7 DISTRIBUTION STATEMENT of the abstr 8. SUPPLEMENTARY NOTES	act enterest in Block 20, it dillerent l	rom Report)
		act enterest in Block 20, it different f	from Report)
		act enterest in Block 20, it dillerent l	rom Report)
	B. SUPPLEMENTARY NOTES 9 KEY WORDS (Continue on reverse side if no Compression Chamber		v) Oxygen Therapy
	8. SUPPLEMENTARY NOTES 9. KEY WORDS (Continue on reverse side if no Compression Chamber Compression Therapy	ecessary and identify by block numbe Medical Mycology <u>Mucor</u>	oxygen Therapy Phycomycosis
	8. SUPPLEMENTARY NOTES 9. KEY WORDS (Continue on reverse side if no Compression Chamber Compression Therapy Hyperbaric Medicine	ecessary and identify by block numbe Medical Mycology <u>Mucor</u> Mucormycosis	v) Oxygen Therapy
	B. SUPPLEMENTARY NOTES 9 KEY WORDS (Continue on reverse side if no Compression Chamber Compression Therapy Hyperbaric Medicine Hyperbaric Oxggenation Hyperbarics	ecessary and identify by block numbe Medical Mycology <u>Mucor</u> <u>Mucormycosis</u> Mycotic Disease Agent Oxygen Pressure	oxygen Therapy Phycomycosis Rhizopus nigricans
	B. SUPPLEMENTARY NOTES 9 KEY WORDS (Continue on reverse side if no Compression Chamber Compression Therapy Hyperbaric Medicine Hyperbaric Oxggenation Hyperbarics - ABSTRACT (Continue on reverse side if ne	ecessary and identify by block number Medical Mycology <u>Mucor</u> <u>Mucormycosis</u> Mycotic Disease Agent Oxygen Pressure cessary and identify by block number	oxygen Therapy Phycomycosis Rhizopus nigricans
	 8. SUPPLEMENTARY NOTES 9. KEY WORDS (Continue on reverse side if no Compression Chamber Compression Therapy Hyperbaric Medicine Hyperbaric Oxggenation Hyperbaries ABSTRACT (Continue on reverse side if ne Plus (+) and minus (~) matin 	ecessary and identify by block number Medical Mycology <u>Mucor</u> <u>Mucormycosis</u> Mycotic Disease Agent <u>Oxygen Pressure</u> cessary and identify by block number g strains of Rhizopus	oxygen Therapy Phycomycosis <u>Rhizopus nigricans</u>
	 8. SUPPLEMENTARY NOTES 9. KEY WORDS (Continue on reverse side if no Compression Chamber Compression Therapy Hyperbaric Medicine Hyperbaric Oxggenation Hyperbarics C. ABSTRACT Continue on reverse side if ne Plus (+) and minus (~) matin yitted for macroscopic and mi baric oxygen levels and for 	ecessary and identify by block number Medical Mycology <u>Mucor</u> <u>Mucormycosis</u> Mycotic Disease Agent <u>Oxygen Pressure</u> cessary and identify by block number g strains of <u>Rhizopus</u> croscopic growth chara various exposure times	or) Oxygen Therapy Phycomycosis <u>Rhizopus nigricans</u> <u>nigricans were observed in</u> cteristics at varying hyper- and intervals. Definite
	 8. SUPPLEMENTARY NOTES 9. KEY WORDS (Continue on reverse side if no Compression Chamber Compression Therapy Hyperbaric Medicine Hyperbaric Oxggenation Hyperbaries C. ABSTRACT Continue on reverse side if ne Plus (+) and minus (-) matin Vitre for macroscopic and mi baric exvgen levels and for inhibition of both strains w 	ecessary and identify by block number Medical Mycology <u>Mucor</u> <u>Mucormycosis</u> Mycotic Disease Agent <u>Oxygen Pressure</u> <u>cessary and identify by block number</u> g strains of <u>Rhizopus</u> croscopic growth chara various exposure times as observed within oxy	^(r) Oxygen Therapy Phycomycosis <u>Rhizopus nigricans</u> <u>nigricans</u> were observed <u>in</u> cteristics at varying hyper- and intervals. Definite gen levels well tolerated by
	 B. SUPPLEMENTARY NOTES SUPPLEMENTARY NOTES SUPPLEMENTARY NOTES Compression Chamber Compression Chamber Compression Therapy Hyperbaric Medicine Hyperbaric Oxggenation Hyperbaries C. ABSTRACT Continue on reverse side if ne Plus (+) and minus (-) matin Vitre for macroscopic and mi baric oxygen levels and for inhibition of both strains w human. Overall experimenta 	ecessary and identify by block number Medical Mycology <u>Mucor</u> <u>Mucormycosis</u> Mycotic Disease Agent <u>Oxygen Pressure</u> <u>cessary and identify by block number</u> g strains of <u>Rhizopus</u> croscopic growth chara various exposure times as observed within oxy 1 results provide in y	^(r) Oxygen Therapy Phycomycosis <u>Rhizopus nigricans</u> <u>nigricans were observed in</u> cteristics at varying hyper- and intervals. Definite gen levels well tolerated by itro basis for use of com-
	 8. SUPPLEMENTARY NOTES 9. KEY WORDS (Continue on reverse side if no Compression Chamber Compression Therapy Hyperbaric Medicine Hyperbaric Oxggenation Hyperbaries C. ABSTRACT Continue on reverse side if ne Plus (+) and minus (-) matin Vitre for macroscopic and mi baric exvgen levels and for inhibition of both strains w 	ecessary and identify by block number Medical Mycology <u>Mucor</u> <u>Mucormycosis</u> Mycotic Disease Agent <u>Oxygen Pressure</u> <u>cessary and identify by block number</u> g strains of <u>Rhizopus</u> croscopic growth chara various exposure times as observed within oxy 1 results provide in y	^(r) Oxygen Therapy Phycomycosis <u>Rhizopus nigricans</u> <u>nigricans were observed in</u> cteristics at varying hyper- and intervals. Definite gen levels well tolerated by itro basis for use of com-
	 B. SUPPLEMENTARY NOTES REY WORDS (Continue on reverse side if in Compression Chamber Compression Therapy Hyperbaric Medicine Hyperbaric Oxggenation Hyperbaries ABSTRACT Continue on reverse side if ne Plus (+) and minus (~) matin vitre for macroscopic and mi baric oxygen levels and for inhibition of both strains w human. Overall experimenta offession chamber therapy in nigricans. 	ecessary and identify by block number Medical Mycology <u>Mucor</u> <u>Mucormycosis</u> Mycotic Disease Agent <u>Oxygen Pressure</u> <u>cessary and identify by block number</u> g strains of <u>Rhizopus</u> croscopic growth chara various exposure times as observed within oxy 1 results provide in y	^(r) Oxygen Therapy Phycomycosis <u>Rhizopus nigricans</u> <u>nigricans were observed in</u> cteristics at varying hyper- and intervals. Definite gen levels well tolerated by itro basis for use of com-
	 B. SUPPLEMENTARY NOTES REY WORDS (Continue on reverse side if no Compression Chamber Compression Therapy Hyperbaric Medicine Hyperbaric Oxggenation Hyperbaries ABSTRACT (Continue on reverse side if ne Plus (+) and minus (-) matin vitre for macroscopic and mi baric oxygen levels and for inhibition of both strains w homans. Overall experimenta pression chamber therapy in 	eccessary and identify by block number Medical Mycology <u>Mucor</u> <u>Mucormycosis</u> Mycotic Disease Agent <u>Oxygen Pressure</u> cessary and identify by block number g strains of <u>Rhizopus</u> croscopic growth chara various exposure times as observed within oxy l results provide <u>in v</u> treatment of mucormyco	^(r) Oxygen Therapy Phycomycosis <u>Rhizopus nigricans</u> <u>nigricans were observed in</u> cteristics at varying hyper- and intervals. Definite gen levels well tolerated by <u>itro basis for use of com-</u> sis caused by <u>Rhizopus</u>
	 B. SUPPLEMENTARY NOTES REY WORDS (Continue on reverse side if in Compression Chamber Compression Therapy Hyperbaric Medicine Hyperbaric Oxggenation Hyperbaries ABSTRACT Continue on reverse side if ne Plus (+) and minus (~) matin vitre for macroscopic and mi baric oxygen levels and for inhibition of both strains w human. Overall experimenta offession chamber therapy in nigricans. 	ecessary and identify by block number Medical Mycology <u>Mucor</u> <u>Mucormycosis</u> Mycotic Disease Agent Oxygen Pressure cessary and identify by block number g strains of <u>Rhizopus</u> croscopic growth chara various exposure times as observed within oxy l results provide <u>in v</u> treatment of mucormyco	^(r) Oxygen Therapy Phycomycosis <u>Rhizopus nigricans</u> <u>nigricans</u> were observed <u>in</u> cteristics at varying hyper- and intervals. Definite gen levels well tolerated by <u>itro</u> basis for use of com- sis caused by <u>Rhizopus</u>
	 B. SUPPLEMENTARY NOTES REY WORDS (Continue on reverse side if in Compression Chamber Compression Therapy Hyperbaric Medicine Hyperbaric Oxggenation Hyperbaries ABSTRACT Continue on reverse side if ne Plus (+) and minus (~) matin vitre for macroscopic and mi baric oxygen levels and for inhibition of both strains w human. Overall experimenta offession chamber therapy in nigricans. 	ecessary and identify by block number Medical Mycology <u>Mucor</u> <u>Mucormycosis</u> Mycotic Disease Agent <u>Oxygen Pressure</u> cossary and identify by block number g strains of <u>Rhizopus</u> croscopic growth chara various exposure times as observed within oxy 1 results provide in y treatment of mucormyco	^(r) Oxygen Therapy Phycomycosis <u>Rhizopus nigricans</u> <u>nigricans</u> were observed <u>in</u> cteristics at varying hyper- and intervals. Definite gen levels well tolerated by <u>itro</u> basis for use of com- sis caused by <u>Rhizopus</u>

÷*

•

FJSRL-TR-80-006

ĩ

¥.(

7

THE EFFECT OF HYPERBARIC OXYGEN ON

THE GROWTH OF RHIZOPUS NIGRICANS

ΒY

MAJOR WILLIAM J. CAIRNEY LIEUTENANT KAREN A. O'HAIR

DECEMBER 1980

DEPARTMENT OF BIOLOGY U. S. AIR FORCE ACADEMY, COLORADO 80840

TABLE OF CONTENTS

SECTION													PAGE	
INTRODUCTION	•	•	•	•	•	•	•	•	•	•	•	•	1	
MATERIALS AND MET	THC	DDS	3	•	•	•	•	•	•	•	•	•	2	
RESULTS	•	•	•	•	•	•	•	•	•	•	•	•	4	
DISCUSSION	•	•	•	•	•	•	•	•	•	•	•	•	6	
ACKNOWLEDGEMENTS	•	•	•	•	•	•	•	•	•	•	•	•	7	
REFERENCES	•	•	•	•	•	•	•	•	•	•	•	•	8	
FIGURES	•	•	•	•	•	•	•	•	•	•	•	•	9	

i

200

• ~

ŗ,

Accession Fer NTIS GRA&I DTIC TAB Unannowneed 1.1 Justification \square By_____ Districution/ Availab Lity Codes Digg the country of and for

INTRODUCTION

Hyperbarie oxygen has been used effectively for almost two decades for treatment of anaerobic infections (e.g. clostridial myonecrosis) and carbon monoxide poisoning. In the late 1960's, reputable research facilities began reporting clinical successes in the use of hyperbaric oxygen for treatment of <u>Pseudomonas</u> infections secondary to burns, osteogenesis enhancement in bone grafts, osteomyelitis, maxillofacial osteoradienccresis, and preservation of failing skin grafts (7). Successful treatment of infections caused by aerobic organisms including several fungi has prompted some recent research efforts to further investigate the effect of hyperbaric oxygen on mycotic disease agents. Cairney has reported the effects of hyperbaric oxygen on <u>Aspergillus</u> fumigatus, <u>Candida albicans</u>, several species of dermatophytes, and <u>Mucor</u> sp. (2,3,4,5).

Treatment of mucomycotic disease agents with hyperbaric oxygen has attracted special interest. Two cases of mucormycosis have been treated at the Hyperbaric Medicine Division, USAF School of Aerospace Medicine. Hyperbaric exvgen was used as a last resort treatment in both cases, but in each case the mycosis cleared (6). Baker reports that the predominant organism isolated from patients with mucormycosis is <u>Rhizopus</u>, not <u>Mucor</u>. <u>Khizopus oryzae</u>, <u>R. arrhizus</u>, <u>R. nigricans</u>, <u>R. rhizopodiformis</u>, and <u>R. microsporus have all been cultured from human subjects (1).</u>

Perhaps the most extensive study of the reactions of fungi to hyperbaric oxygen was carried out by Robb (8). Robb exposed 103 species of tunni to 10 atmospheres oxygen pressure at 25°C for 7 days. This exposure is well in excess of established human oxygen tolerance limits. The second as reports in the literature of the reaction of <u>Rhizopus</u> spp. to hyperbaric oxygen at PO2 levels not toxic to humans. The purpose of this study was to determine the growth rate and observe the macroscopic and microscopic appearance of <u>Rhizopus nigricans</u> grown in culture under various hyperbaric oxygen levels.

MATERIALS AND METHODS

Three experiments were undertaken to determine the effects of hyperbaric oxygen on <u>Rhizopus nigricans</u>. Isolates of the fungus (+ and mating strains) were obtained from the American Type Culture Collection. Fotato dextrose agar (PDA) was used as a culture medium in all experiments. All exposures of the organisms to increased oxygen were carried out in a table top (31 liter capacity) hyperbaric chamber made available for the project by the Aerospace Pathology Branch of the Armed Forces Institute of Pathology.

In all experiments, organisms were compressed to the desired pressure in less than 30 seconds. Following compression, the chamber was flushed rapidly with five chamber volumes of 100% oxygen to insure a pure oxygen environment. Each time the chamber was decompressed for removal of cultures, this same flushing operation was performed upon recompression. During compression periods, a 5-liter/hour flow was maintained through the system.

Organisms to be exposed to oxygen, along with controls, were propagated from growing hyphal tips. In the first two experiments agar biplates were used. The two compartments contained the + and - strains, respectively. In the last experiment, each undivided plate contained a + and - strain of <u>Rhizopus nigricans</u>. No inhibitors of any kind were incorporated into the medium in order to keep variables to a minimum. The pH of the medium was 5.6. The room in which the experiments were performed was maintained at 25° (\pm 1°) C. Cultures were exposed to external fluorescent light for the duration of all experiments. The hyperbaric chamber, constructed of transparent plexiglass, allowed exposures of organisms to external light.

In the first experiment, + and - strains of <u>Khizopus nigricans</u> were placed in the hyperbaric chamber and exposed to a steady 1-ATA (one atmosphere absolute) level of oxygen. Controls were allowed to grow at room pressure. Three 1-ATA air control plates (12 potential colonies) and three 1-ATA level of oxygen plates (12 potential colonies) were used for the first experiment. To insure growth, all colonies were allowed to incubate 48 hours before placing the 100% oxygen plates into the chamber. All plates were surveyed visually for macroscopic growth at 24-hour intervals for three days. Two additional readings were taken on the 11th and 18th day after inoculation.

In the second experiment, <u>Rhizopus nigricans</u> cultures were exposed to hyperbaric oxygen according to standard exposure tables used for treating gas gangreae resulting from <u>Clostridium</u> spp. (especially <u>Clostridium perfringens</u>) infections (3,4). As in the first experiment, <u>Petri dishes containing 24-hour cultures of + and - <u>Rhizopus nigricans</u> were used. Three plates (12 potential colonies) were used for chamber exposure. Three plates (12 potential colonies) were used as 1-ATA air outrols.</u>

The experimental plates were exposed to 3-ATA oxygen for three 90-minute periods during the first 24 hours. In each of two succeeding 24-hour periods, cultures were exposed to the same 3-ATA level for two 90-minute periods. Cultures were thus exposed to seven 90-minute periods of oxygen at S-ATA over a span of three days. Organisms were checked for growth throughout the experiment and measurements were made on the first, third, Sixth, and eighth days after inoculation.

in the tail experiment, <u>Rhizopus nigricans</u> cultures were also exposed to hyperbaric oxygen according to exposure tables used for treating gas gangrene, but exposure of some plates was continued for two 90-minute

periods per day for up to two additional days. Cultures were thus exposed to seven, nine, or eleven 90-minute periods of oxygen at 3-ATA over a span of three, four, or five days, respectively. Undivided plates were used. One colony of each strain (+ and -) were placed together on each Petri dish. Ten plates (20 potential colonies) were exposed to the standard treatment table. Six plates (12 potential colonies) followed the standard exposure treatment table plus two 90-minute exposures during an additional 24 hours. Five plates (10 potential colonies) were exposed to the standard treatment table then given four additional 90-minute exposures, two exposures during each of the next 24-hour periods. Six plates (12 potential colonies) were maintained as 1-ATA air controls.

Plates to be exposed were placed in the chamber 24 hours after inoculation. Measurements of the controls and the standard treatment table plates began on the fourth day after inoculation. The other plates were measured on the day their scheduled exposure were completed. All measurements of the colonies were taken until the eleventh day after inoculation.

In each of the three experiments air pressurized controls (3-ATA) were run at a separate time but under otherwise identical conditions to insure that any observed effects were caused by oxygen rather than by total pressure. In each case, the number of compressed air control plates equaled the number of plates exposed to pressurized oxygen. Exposure to 3-ATA compressed air resulted in no significant differences in growth rates between exposure plates and 1-ATA air controls.

RESULTS

Growth curves for all organisms in the 1-ATA experiment are shown in figures 1 and 2. Growth curves for the first "treatment table" experiment are shown in figures 3 and 4. Growth curves for the second

"treatment table" exposures are shown in figures 5 and 6. Fungi exposed to identical conditions (whether on the same actual Petri plate or not) grew to the same extent over a given time interval. An upper limit was established for the diameter of the colony, 50mm. Once a colony had reached this size no more readings were taken. This upper limit was mandated by the size of the Petri plate.

Exposure to 1-ATA oxygen resulted in no significant differences in growth rates between exposed plates and controls. However, there is a marked difference between the growth rates of + and - strains overall. The - strain of <u>Rhizopus nigricans</u> grew at a much faster rate, always reaching 50mm in size. The + strain never reached a 50mm diameter size in either chamber or control plates. This fact was evident in not only the 1-ATA experiment but also in the other experiments.

Figures 3 through 6, from the second experiment, show that the -<u>Rhizopus nigricans</u> growth, while not inhibited altogether, is at least retarded. The exposed + <u>Rhizopus nigricans</u>, however, grew at a faster <u>apparent</u> rate than the controls. One major reason for this was the starttog size of the <u>R</u>. <u>nigricans</u> + colonies when placed in the chamber. The plates destined for the chamber were specifically picked because of the size of the <u>+</u> strain colonies. Due to the somewhat less dependable growth characteristics of the <u>R</u>. <u>nigricans</u> + strain, vigorus growth had to be assured before the organism was exposed to hyperbaric oxygen. An admitted bias was therefore present in this experiment in favor of the + strain. One significant developmental feature was that sporangial growth was delayed in all exposed colonies compared to the controls for the <u>R</u>. <u>nigricans</u> - strain. The <u>R</u>. <u>nigricans</u> + strain never showed any sporangial growth during any of the experiments.

The third experiment results second to partially contradict the results from the second experiment. The plates exposed to the standard treatment table showed no significant difference between their growth rate for both the + and - <u>Rhizopus nigricans</u> and the controls. Sporangia, furthermore, were formed after the same interval after inoculation in both the standard treatment exposures and the controls. However, as the number of days of exposure increased, the difference between the growth rate of the exposed organisms to the control organisms increased. Also, the delay in formation of sporangia was observed to increase with the number of additional days of exposure.

One observation, however, was consistent in the 3-ATA hyperbaric oxygen experiments. The density of growth was much less for fungion the exposed plates than on the controls while the former were undergoing hyperbaric oxygen treatment. The hyperbaric oxygen-treated colonies were sparsely matted and were tending to grow into agar rather than on the surface. The controls were thickly matted and largely growing on the surface. After the exposed colonies were removed from hyperbaric oxygen, lowever, they started growing on the surface and quickly became thickly matted.

DISCUSSION

The intent of this investigation is to establish an <u>in vitro</u> evtological basis for treating cases of mucormycosis in hyperbaric chambers. To some extent, that basis has been established. The growth of <u>Rhizopus</u> <u>nigricans</u> was at least retarded by oxygen levels well tolerated by humans.

The 1-ATA oxygen exposure, had it had an effect, would have at least suggested the possibility of treatment with 100% oxygen without the need for additional pressurization.

The demonstration of an effect using a standard treatment table is significant and the effect of the hyperbaric oxygen might be greatly enhanced with systemic antifungal agents used between oxygen exposures. Unpublished data by Simon (9) suggest that some antifungal agents, including Amphotericin B, may actually be degraded by exposure to hyperbaric oxygen. One or more of the breakdown products may be metabolites. Should this be confirmed in future work, combining hyperbaric oxygen with systemic antifungal agents administered at the same time might not be advisable.


Follow-on <u>in vivo</u> hyperbaric oxygenation studies testing mucormycotic agents, especially <u>Rhizopus</u> spp. would supply additional helpful information. For future <u>in vitro</u> work, Elliott (this laboratory) is developing **a** highly precise liquid culture technique for assessing the developmental effects of hyperbaric oxygen on human pathogenic fungi in culture.


ACKNOWLEDGEMENTS

The authors gratefully acknowledge the support of Dr. Gary R. Coulter, Associate Professor of Biology, Dr. Lawrence J. Biever, Assistant Professor of Biology, both of the USAF Academy, and Dr. Kenneth E. Siegenthaler, Director of Chemical Sciences, Frank J. Seiler Research Laboratory, for review of the manuscript and technical advice. The support of Mr. John Scupp and Mr. Michael Petraglia was invaluable for providing laboratory assistance. The authors also appreciate the support of the Frank J. Seiler Research Laboratory in sponsoring this effort. Note: Reference cultures of the + and - mating strains of <u>Rhizopus</u> alignicans used in this study are maintained under oil in the Biology Department (DFB) Culture Collection, USAF Academy, Colorado.


REFERENCES

- Baker, R. D. 1975. The epidemiology of mucormycosis. Chapter 12, Al-Doory, Y., (Ed.): The Epidemiology of Human Mycotic Diseases. 1975. Charles C. Thomas, Publisher, Springfield.
- 2. Cairney, W. J. 1980. Problems associated with meaningful research on the effects of hyperbaric oxygen on mycotic disease agents. Technical Report USAFA-TR-80-2. United States Air Force Academy, Colorado.
- 3. Cairney, W. J. 1980. The effect of hyperbaric oxygen on the growth of <u>Mucor</u> sp. and <u>Aspergillus</u> <u>fumigatus</u>. Technical Report FJSRL-TR-80-004. Frank J. Seiler Research Laboratory, USAF Academy, Colorado.
- Cairney, W. J. 1980. The effect of hyperbaric oxygen on certain growth features of four dermatophytes. Technical Report FJSRL-TR-80-005. Frank J. Seiler Research Laboratory, USAF Academy, Colorado.
- 5. Cairney, W. J. 1978. Effect of hyperbaric oxygen on certain growth features of <u>Candida albicans</u>. Aviat. Space Environ. Med. 49(8): 956-958.
- 6. Dumn, J. M. 1980. Methodist Hospital Hyperbaric Medicine Division, San Antonio, Texas. Personal communication.
- Heimbach, R. D., J. G. Davis, J. C. Davis, and J. M. Dunn. 1976. Hyperbaric medicine in the U. S. Air Force. Aeromedical Review 6-76. USAF School of Aerospace Medicine, Brooks AFB, Texas.
- 8. Robb, S. M. 1966. Reactions of fungi to exposure to 10 atmospheres pressure of oxygen. J. Gen. Microbial. 45: 17-29.
- 9. Simon, S. M. 1976. Effect of hyperbaric oxygen on certain systemic antifungal agents. Unpublished research data.







TI



.





٠,

